ENGOT Cx8/GOG 3024/innovaTV 205: Interim Phase II Results With Tisotumab Vedotin Combinations in Recurrent or Metastatic Cervical Cancer

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Tisotumab vedotin plus pembrolizumab demonstrated promising, durable antitumor activity with a tolerable safety profile in recurrent or metastatic cervical cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 199 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seagen & Genmab

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings